personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Intravitreal bevazicumab for retinopathy of prematurity: refractive error results

Session Details

Session Title: Vascular Diseases III

Session Date/Time: Sunday 29/09/2013 | 08:00-10:00

Paper Time: 08:32

Venue: Hall 3 (Level 0)

First Author: J.Jonas GERMANY

Co Author(s):    B. Harder   F. Schlihctenbrede   S. von Baltz   W. Jendritza     

Abstract Details

Purpose:

To evaluate refractive error in infants who underwent intravitreal bevacizumab injection for treatment of threshold retinopathy of prematurity (ROP).

Setting:

Hospital-based study

Methods:

The study group included all infants who consecutively received a single intravitreal bevacizumab (0.375 mg or 0.625 mg) injection for therapy of threshold ROP in fundus zone I or zone II. The control group included infants who had previously undergone retinal argon laser therapy of ROP. The follow-up examination included refractometry under cylcoplegic conditions.

Results:

The study group included 12 children (23 eyes; mean birth weight:622±153g; gestational age:25.2±1.6 weeks) and the control group included 13 children (26 eyes; birth weight:717±197g; gestational age:25.3±1.8 weeks). Both groups did not differ significantly in birth age and weight and follow-up. At the end of follow-up at 11.4±2.3 months after birth, refractive error was less myopic in the study group than in the control group (-1.04±4.24 diopters (median:0 diopters) versus -4.41±5.50 diopters (median:-5.50 diopters);P=0.02). Prevalence of moderate myopia (17±8% versus 54±10%; P=0.02; OR:0.18 (95%CI:0.05,0.68) and high myopia (9±6% versus 42±10%;P=0.01; OR:0.13 (95%CI:0.03,0.67) was significantly lower in the bevacizumab group. Refractive astigmatism was significantly lower in the study group (-1.0±1.04 diopters versus 1.82±1.41 diopters; P=0.03). In multivariate analysis, myopic refractive error and astigmatism were significantly associated with laser therapy versus bevacizumab therapy (P=0.04 and P=0.02, respectively).

Conclusions:

In a one-year follow-up, a single intravitreal bevacizumab injection as compared to conventional retinal laser coagulation was helpful for therapy of ROP and led to less myopization and less astigmatism.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy